Patients were assigned alive when direct contact was possible within April to May 2014. Deaths were documented either via hospital discharge documents or via data from insurance companies.

Transplanted patients (n=6) were censored at the time of transplantation in Kaplan-Meier’s selleck screening library analysis. The patients were devided into survivors and deaths. Descripitiv analysis was performed and baseline characteristics of the two cohorts were compared. Furthermore we performed Kaplan-Meier’s survival analysis for MELD (<8; 8-14; >14) and VITRO-score (<1; 1-3.5; ≥3.5). Results: male 86 (66.2%), CPS A: 83.1%, CPS B: 16.2%, CPS C: 0.8%. According to D'Amico 101 (77.6%) were compensated. Median follow-up time was 28 months (0-41; 95% CI) Baseline characteristics are described in table 1. Overall 20 patients (15.4%) died during follow up. Median vWF-Ag, VITRO-score, albumin, CPS and MELD are significantly different in patients ABT-263 ic50 who died compared to survivors. Patients with VITRO-score ≥ 3.5 show significantly worse survival with a one-year mortality of 15% compared to a one-year mortality of 5% in patients with VITRO-score between 1 and 3.5 and 0% in patients with VITRO-score <1 (log-rank<0.003). MELD-score didn't reach statistical significance in our cohort (log-rank 0.141). Conclusion:

VITRO-score is able to predict survival in a cohort of HCV cirrhotic patients and might help to identify patients at risk of dying. Furthermore in our cohort VITRO-score even outplays MELD-score in predicting survial. Baseline characteristics Disclosures: Andreas Maieron – Advisory Committees or Review Panels: MSD, Jannsen, BMS, B√∂hringer Ingelheim, Gilead; Grant/Research Support: Roche; Speaking and Teaching: Roche, MSD, Jannsen, Gilead Stephanie Hametner – Speaking and Teaching: MSD Alexander Ziachehabi – Advisory Committees or Review Panels: MSD; Grant/ Research Support: GILEAD; Speaking and Teaching: MSD The following people have nothing to disclose: Silvia I. Hametner, Monika Ferlitsch, Rainer Schöfl, Arnulf Ferlitsch

Background: Transient elastography based on liver stiffness measurement is a validated non-invasive method to assess hepatic fibrosis in chronic viral hepatits. Evaluation of repro-ducibility and definition of experimented operator are crucial points to the worldwide use of this method. Edoxaban The aims were to evaluate the learning curve and the intraobserver variability in transient elastography in patients with chronic hepatitis C with and without HIV co-infection. Methods: We performed a cross-sectional study, analysing findings from patients who had liver fibrosis assessed by transient elastography twice on the same day performed by a single operator. Learning curve was evaluated comparing intraobserver agreement taking into account the operator experience as poor (< 100 exams); moderate (101-300 exams) and high (> 300 exams). Liver stiffness measurement used to define fibrosis stages, based on METAVIR score, was: <7.1 as F0F1, 7.